<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941964</url>
  </required_header>
  <id_info>
    <org_study_id>M19-072</org_study_id>
    <nct_id>NCT03941964</nct_id>
  </id_info>
  <brief_title>A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy</brief_title>
  <official_title>A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study evaluating the effectiveness and safety of venetoclax, in combination with
      azacitidine or decitabine, in an outpatient setting for treatment-naïve participants with AML
      who are ineligible for intensive chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2019</start_date>
  <completion_date type="Anticipated">February 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Complete Remission Rate (CR + CRi)</measure>
    <time_frame>Up to approximately 24 weeks</time_frame>
    <description>The Composite Complete Remission Rate (CR + CRi) is defined as the proportion of participants who achieve complete remission (CR) plus participants who achieve complete remission with incomplete hematologic recovery (CRi) as described by the modified International Working Group (IWG) criteria for Acute Myeloid Leukemia (AML).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rates (CR, CRi)</measure>
    <time_frame>Up to approximately 24 weeks</time_frame>
    <description>Overall Response Rates to treatment is the proportion of participants who achieve complete remission or complete remission with incomplete hematologic recovery, based on guidelines adapted from the IWG for AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants who Achieve Transfusion Independence</measure>
    <time_frame>Up to at least 56 days after initial administration of study drug</time_frame>
    <description>Transfusion Independence: the rate of red blood cell (RBC) and platelet transfusion dependence (defined as having received ≥ 2 units of RBCs and/or platelets within 56 days prior to study) at baseline and assess transfusion independence, defined as at least 56 consecutive days without a RBC or platelet transfusion during the treatment period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Ventoclax + azacitidine or decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax (daily for 28 days), in combination with azacitidine or decitabine, beginning on Cycle 1 Day 1. Depending on investigator's choice, participants will receive either azacitidine for 7 days beginning on Day 1 of each 28-day cycle or decitabine for 5 days beginning on Day 1 of each 28-day cycle, as per institutional practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venetoclax</intervention_name>
    <description>tablet; oral</description>
    <arm_group_label>Ventoclax + azacitidine or decitabine</arm_group_label>
    <other_name>ABT-199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacytidine</intervention_name>
    <description>infusion; subcutaneous or intravenous</description>
    <arm_group_label>Ventoclax + azacitidine or decitabine</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <description>infusion; intravenous</description>
    <arm_group_label>Ventoclax + azacitidine or decitabine</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has confirmation of acute myeloid leukemia (AML) by World Health
             Organization (WHO) criteria.

          -  Participant is deemed by the investigator to be an appropriate candidate for
             outpatient ramp-up of venetoclax.

          -  Participant is not eligible to receive treatment with standard cytarabine and
             anthracycline induction regimens.

          -  Participant has not received prior treatment for AML (treatment naïve) with the
             exception of hydroxyurea.

          -  Participant has no evidence of spontaneous tumor lysis syndrome (TLS) at Screening.

          -  Participant can have progressed from myelodysplastic syndrome (MDS) or be considered
             to have secondary AML and could have been treated with growth factors or other agents
             with the exception of hypomethylating agents.

          -  Participant has adequate kidney, liver and hematology laboratory values as detailed in
             the protocol.

          -  Has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 3.

        Exclusion Criteria:

        - Has a history of the following conditions:

          -  Acute promyelocytic leukemia

          -  Known active central nervous system involvement with AML

          -  Positive for HIV (HIV testing is not required)

          -  Positive for hepatitis B or C infection with the exception of those with an
             undetectable viral load within 3 months

          -  Cardiovascular disability status of New York Heart Association Class &gt; 2

          -  Chronic respiratory disease that requires continuous oxygen or any other medical
             condition that in the opinion of the investigator would adversely affect his/her
             participating in this study

          -  Malabsorption syndrome or other condition that precludes enteral route of
             administration

        Has a history of other malignancies within 2 years prior to study entry, with the exception
        of:

          -  Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of
             breast

          -  Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin

          -  Previous malignancy confined and surgically resected (or treated with other
             modalities) with curative intent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC-HOPE /ID# 211509</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711-2701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute /ID# 212800</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers /ID# 211508</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA /ID# 212837</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc - Kenwood /ID# 212779</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236-2725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute /ID# 211504</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401-6043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates, PA /ID# 211471</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414-7710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System - Int'l Dr /ID# 211466</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Chattanooga / McCallie /ID# 212717</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404-3230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology-Nashville Centennial /ID# 210944</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203-1632</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Midtown /ID# 212780</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Medical City Dallas /ID# 211503</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute /ID# 213311</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Medical Center /ID# 211510</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240-5251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler /ID# 213908</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia (AML)</keyword>
  <keyword>cancer</keyword>
  <keyword>treatment naive</keyword>
  <keyword>venetoclax</keyword>
  <keyword>azacitidine</keyword>
  <keyword>decitabine</keyword>
  <keyword>outpatient setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

